Tessari Eben's most recent trade in Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A was a trade of 16,044 Class A Ordinary Share done at an average price of $36.5 . Disclosure was reported to the exchange on Sept. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 36.45 per share. | 15 Sep 2025 | 16,044 | 34,908 (0%) | 0% | 36.5 | 584,804 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 15 Sep 2025 | 6,500 | 50,952 (0%) | 0% | 8.8 | 57,395 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2025 | 6,500 | 19,000 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 37.00 per share. | 15 Sep 2025 | 356 | 34,552 (0%) | 0% | 37 | 13,172 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 35.52 per share. | 04 Sep 2025 | 85,271 | 44,452 (0%) | 0% | 35.5 | 3,028,826 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 04 Sep 2025 | 46,546 | 129,723 (0%) | 0% | 15.5 | 722,394 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2025 | 46,546 | 13,389 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 04 Sep 2025 | 38,725 | 83,177 (0%) | 0% | 15.5 | 600,238 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2025 | 38,725 | 6,249 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 04 Sep 2025 | 13,389 | 57,841 (0%) | 0% | 15.5 | 207,797 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2025 | 13,389 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 35.66 per share. | 04 Sep 2025 | 13,389 | 44,452 (0%) | 0% | 35.7 | 477,452 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 39,364 | 39,364 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 35.50 per share. | 01 Sep 2025 | 15,091 | 44,452 (0%) | 0% | 35.5 | 535,731 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 15,026 | 44,974 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 01 Sep 2025 | 15,026 | 59,543 (0%) | 0% | 15.5 | 232,903 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 9,828 | 9,828 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.49 per share. | 01 Sep 2025 | 3,022 | 43,438 (0%) | 0% | 33.5 | 101,207 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 2,726 | 2,726 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 2,726 | 46,460 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,964 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,964 | 45,402 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,773 | 3,545 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,773 | 43,734 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,746 | 5,235 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,746 | 41,961 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.28 per share. | 01 Sep 2025 | 950 | 44,452 (0%) | 0% | 34.3 | 32,566 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 65 | 59,935 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 01 Sep 2025 | 65 | 44,517 (0%) | 0% | 15.5 | 1,009 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 33.77 per share. | 18 Aug 2025 | 16,100 | 40,315 (0%) | 0% | 33.8 | 543,697 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 6,500 | 25,500 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 18 Aug 2025 | 6,500 | 56,415 (0%) | 0% | 8.8 | 57,395 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 34.44 per share. | 18 Aug 2025 | 100 | 40,215 (0%) | 0% | 34.4 | 3,444 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 33.20 per share. | 15 Jul 2025 | 138,064 | 50,465 (0%) | 0% | 33.2 | 4,583,725 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 38,928 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.36 per share. | 15 Jul 2025 | 38,928 | 88,843 (0%) | 0% | 10.4 | 403,294 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 32,710 | 32,710 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.10 per share. | 15 Jul 2025 | 32,710 | 151,997 (0%) | 0% | 11.1 | 363,081 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 30,444 | 16,694 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.97 per share. | 15 Jul 2025 | 30,444 | 119,287 (0%) | 0% | 13.0 | 394,859 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 25,896 | 39,524 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 15 Jul 2025 | 25,896 | 177,893 (0%) | 0% | 12.0 | 309,975 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 10,636 | 31,908 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.76 per share. | 15 Jul 2025 | 10,636 | 188,529 (0%) | 0% | 10.8 | 114,443 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 15.63 per share. | 15 Jul 2025 | 752 | 49,915 (0%) | 0% | 15.6 | 11,754 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 33.90 per share. | 15 Jul 2025 | 550 | 49,915 (0%) | 0% | 33.9 | 18,645 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 28.72 per share. | 14 Jul 2025 | 18,900 | 49,163 (0%) | 0% | 28.7 | 542,808 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 14 Jul 2025 | 6,500 | 68,063 (0%) | 0% | 8.8 | 57,395 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2025 | 6,500 | 32,000 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 28.28 per share. | 16 Jun 2025 | 17,300 | 61,563 (0%) | 0% | 28.3 | 489,244 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 6,500 | 38,500 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 16 Jun 2025 | 6,500 | 78,863 (0%) | 0% | 8.8 | 57,395 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 45,042 | 38,928 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 30.51 per share. | 09 Jun 2025 | 45,042 | 72,363 (0%) | 0% | 30.5 | 1,374,231 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.36 per share. | 09 Jun 2025 | 45,042 | 117,405 (0%) | 0% | 10.4 | 466,635 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 15,506 | 83,970 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 30.46 per share. | 09 Jun 2025 | 15,506 | 72,363 (0%) | 0% | 30.5 | 472,313 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.36 per share. | 09 Jun 2025 | 15,506 | 87,869 (0%) | 0% | 10.4 | 160,642 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 30.38 per share. | 09 Jun 2025 | 10,319 | 72,363 (0%) | 0% | 30.4 | 313,491 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 10,319 | 99,476 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.36 per share. | 09 Jun 2025 | 10,319 | 82,682 (0%) | 0% | 10.4 | 106,905 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 26.41 per share. | 19 May 2025 | 12,000 | 72,363 (0%) | 0% | 26.4 | 316,920 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 7,000 | 49 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 19 May 2025 | 7,000 | 84,363 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 8,302 | 8,302 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 8,042 | 8,042 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,224 | 5,224 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,975 | 4,975 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 7,000 | 7,049 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 14 Apr 2025 | 7,000 | 89,363 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 20.74 per share. | 14 Apr 2025 | 6,421 | 77,363 (0%) | 0% | 20.7 | 133,172 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 20.19 per share. | 14 Apr 2025 | 5,579 | 83,784 (0%) | 0% | 20.2 | 112,640 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 2,726 | 2,726 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 2,726 | 83,164 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 07 Apr 2025 | 801 | 82,363 (0%) | 0% | 20.3 | 16,244 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 39,364 | 39,364 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 19,657 | 19,657 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 9,828 | 9,828 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,773 | 79,726 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,773 | 3,545 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,746 | 5,235 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,746 | 81,472 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 521 | 80,951 (0%) | 0% | 21.8 | 11,342 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 513 | 80,438 (0%) | 0% | 21.8 | 11,168 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 1,964 | 78,530 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 1,964 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.61 per share. | 16 Mar 2025 | 577 | 77,953 (0%) | 0% | 22.6 | 13,046 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 21.06 per share. | 10 Mar 2025 | 12,409 | 76,566 (0%) | 0% | 21.1 | 261,334 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 10 Mar 2025 | 7,000 | 88,975 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 7,000 | 14,049 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 19.57 per share. | 10 Feb 2025 | 14,000 | 81,975 (0%) | 0% | 19.6 | 273,980 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 10 Feb 2025 | 7,000 | 95,975 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 7,000 | 21,049 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 18.13 per share. | 13 Jan 2025 | 12,323 | 90,652 (0%) | 0% | 18.1 | 223,416 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 13 Jan 2025 | 7,000 | 102,975 (0%) | 0% | 3.8 | 26,600 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 7,000 | 28,049 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 19.08 per share. | 13 Jan 2025 | 1,677 | 88,975 (0%) | 0% | 19.1 | 31,997 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Tessari Eben | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 20.44 per share. | 16 Dec 2024 | 23,017 | 95,975 (0%) | 0% | 20.4 | 470,467 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Tessari Eben | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 16 Dec 2024 | 16,017 | 118,992 (0%) | 0% | 1.6 | 25,467 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals | Tessari Eben | CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 16,017 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals | Eben Tessari | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 21.04 per share. | 18 Nov 2024 | 17,000 | 102,975 (0%) | 0% | 21.0 | 357,680 | Class A Ordinary Share |